At Synergy NeuroPsychiatry, we offer SPRAVATO® as part of our physician-led approach to treatment-resistant depression.
For some adults, depression symptoms may remain difficult to manage despite prior treatment. SPRAVATO® may be considered after a careful psychiatric evaluation of your diagnosis, treatment history, current symptoms, medical background, and individual care needs.
Our goal is to help you understand whether this option may fit within a broader psychiatric care plan.
Treatment-Resistant Depression (TRD): For individuals who have not achieved sufficient symptom relief despite trying at least two other antidepressant therapies.
Major Depressive Disorder (MDD) with Acute Suicidal Ideation or Behavior: A prompt-acting treatment option for those experiencing intense depressive episodes with immediate safety concerns.
Depending on the individual treatment plan, SPRAVATO® may be used alone or alongside an oral antidepressant. It is considered within a broader psychiatric treatment conversation, not as an automatic next step for every person with depression.
At Synergy NeuroPsychiatry, we take time to understand what you have already tried, how symptoms are affecting daily life, and what type of support may be appropriate next.
Depression can affect mood, motivation, concentration, sleep, energy, relationships, and everyday responsibilities. When prior treatment has not provided enough support, it can be frustrating and discouraging.
SPRAVATO® may be considered for eligible adults with treatment-resistant depression. A careful evaluation helps us understand the full picture, including:
An evaluation does not mean SPRAVATO® will automatically be recommended. It is an opportunity to discuss whether it may be appropriate as part of your care plan.
SPRAVATO® is self-administered under direct healthcare-provider supervision in a certified healthcare setting.
Patients are monitored for at least two hours after administration. SPRAVATO® is not dispensed for home use, and patients should not drive, operate machinery, or take part in activities that require full alertness until the next day after a restful sleep.
We will discuss the practical requirements of treatment and answer questions about what to expect before SPRAVATO® is considered.
At Synergy NeuroPsychiatry, SPRAVATO® is considered through a physician-led psychiatric evaluation.
We look at the whole clinical picture rather than focusing on one symptom alone. That includes treatment history, current symptoms, medication response, medical context, and the ways depression is affecting your life.
When appropriate, we may also coordinate with other clinicians involved in your care. Our role is to provide clear information and individualized recommendations without pressure.
SPRAVATO® is not appropriate for everyone. Before treatment is considered, a clinician should review your health history, current medications, blood-pressure considerations, substance-use history, and other relevant safety factors.
The FDA label includes serious warnings related to sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors. Blood pressure can increase after administration. Reported effects may include dizziness, nausea, sedation, dissociation, vertigo, and headache.
This is not a complete list of risks or possible effects. Your clinician can discuss the considerations most relevant to your health history and treatment plan.
Esketamine nasal spray has been studied in adults with treatment-resistant depression.
Research supports discussing SPRAVATO® as an option for selected patients within its FDA-approved use. Individual response can vary, and no specific outcome can be guaranteed.
Our approach is to consider the available evidence alongside your diagnosis, treatment history, safety profile, and individual clinical needs.
Begin with a no-obligation phone consultation. If initial criteria are met, our mental health professionals will conduct a full clinical review, including your treatment background. If eligible, we assist in confirming your insurance benefits with participating providers.
Once coverage is verified, your treatment begins. Each SPRAVATO® session is administered under strict medical oversight. Patients self-administer the nasal spray while being monitored in a controlled, supportive environment for at least two hours.
Your treatment typically begins with twice-weekly sessions in the induction phase. This gradually transitions into a personalized maintenance schedule, based on your progress and long-term goals.
We continue to support your recovery through regular follow-ups. Adjustments to your treatment plan will be made as needed. We also maintain communication with your other healthcare providers to ensure cohesive, coordinated care.
Week 1-4
2 Treatments a Week
Week 5-8
1 Treatments a Week
Week 9+
Treatment frequency will be determined based on patients needs.
Response Rate: Traditional antidepressants typically show a response rate of 40-60%, while SPRAVATO® (esketamine) has demonstrated response rates of up to 70% in clinical trials (Popova et al., 2019, American Journal of Psychiatry).
Time to Noticeable Effect: Traditional antidepressants often take 4-6 weeks for noticeable improvements, whereas patients using SPRAVATO® (esketamine) may experience relief within 24 hours, as observed in clinical trials (BMC Psychiatry, 2022).
Sustained Remission Rate: Traditional antidepressants achieve sustained remission rates of approximately 15-30%, but SPRAVATO® has shown remission rates as high as 80% when combined with an oral antidepressant (Wilkinson et al., 2018, Nature Reviews Drug Discovery).
We follow FDA guidance and use only approved therapies. While some clinics may use off-label ketamine, we focus exclusively on treatments backed by clinical research.
Healing is influenced by surroundings. Our clinic is designed with calming, thoughtful aesthetics to support your well-being throughout treatment.
If you’re already working with a therapist or psychiatrist, we ensure full coordination so all aspects of your care work in harmony.
We work with your insurance and handle all necessary paperwork.
Transformation: What 3,000+ People Who Finally Found Relief With SPRAVATO® Have to Say
Explore the inspiring journeys of individuals who have transformed their lives through the clinical use of SPRAVATO®. From overcoming obstacles to reaching significant milestones, these individuals share how SPRAVATO® treatment has been instrumental in reshaping their habits and creating lasting change. Discover real-life stories of success, motivation, and the powerful impact of building sustainable habits for a better life.
Over 3,000+ residents have used SPRAVATO® to elevate their lives.
If you are living with treatment-resistant depression and want to learn whether SPRAVATO® may be appropriate, we are here to help you explore your options with clarity and clinical guidance.
Download our comprehensive PDF guides to learn about SPRAVATO®, its benefits, uses, and other important safety information.
U.S. Food and Drug Administration. SPRAVATO® Prescribing Information.
SPRAVATO® REMS. SPRAVATO® REMS Program Overview.
Popova, V., et al. “Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression.” American Journal of Psychiatry, 2019.
If you are looking for psychiatry, medication management, or advanced outpatient treatment options in the Kalamazoo area, contact Synergy NeuroPsychiatry to learn more about care options.
